Use of extended-release niacin in clinical practice

Future Lipidology

Volumn 3, Issue 1, 2008, Pages 9-16

  Suryadevara, Ramya S ^a   Karas, Richard H ^a   Kuvin, Jeffrey T ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Extended release niacin; Niacin; Niaspan ; Safety; Tolerability

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CATALASE; CLOFIBRATE; COLESTIPOL; DEXTROTHYROXINE; DIACYLGLYCEROL ACYLTRANSFERASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN; FIBRINOGEN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PLACEBO; PROSTAGLANDIN D2; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL LIPASE; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL PAIN; ACANTHOSIS NIGRICANS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CANADA; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME INHIBITION; FIRST PASS EFFECT; FLUSHING; FOLLOW UP; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; LIVER DYSFUNCTION; LIVER TOXICITY; LOW FAT DIET; METABOLIC SYNDROME X; MIGRAINE; MONOTHERAPY; MUSCULOSKELETAL PAIN; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EID: 40749127903     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.3.1.9     Document Type: Review

References (39)

1. Clofibrate and Niacin in Coronary Heart Disease. JAMA 231, 360-381 (1975).
2. Atac IA, Peksel A, Yanardag R, et al.: The effect of combined treatment with niacin and chromium (III) chloride on different tissues of hyperlipemic rats. Drug Chem. Toxicol. 29, 363-377 (2006).
3. Kuvin JT, Dave DM, Sliney KA et al.: Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am. J. Cardiol. 98, 743-745 (2006).
4. Tavintharan S, Sivakumar M, Lim SC et al.: Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in HepG2cells. Clin. Chim. Acta 376, 41-44 (2007).
5. Kuvin JT, Ramet ME, Patel AR et al.: A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthose expression. Am. Heart J. 144, 1245-1255 (2002).
6. Tunaru S, Kero J, Schaub A et al.: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9, 352-355 (2003).
7. Pike NB: Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J. Clin. Inv. 115, 3400-3403 (2005).
8. Wang W, Basinger A. Neese RA: Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am. J. Physiol. Endocrinol. Metab. 280(3), E540-E547 (2001).
9. Jin FY, Kamanna VS, Kashyap ML et al.: Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. 19(4), 1051-1059 (1999).
10. Ganji SH, Tavintharan S, Zu D et al.: Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J. Lipid Res. 45(10), 1835-1845 (2004).
11. Brousseau ME, Schaefer FJ, Wolfe ML et al.: Effects of an inhibitor of cholesterol ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350(15), 505-515 (2004)
12. Barter PJ, Caulfield M, Eriksson M et al.: Effect of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109-2122 (2007).
13. Stern RH: The role of nicotinic acid metabolites in flushing and hepatotoxicity. J. Clin. Lipidol. 1, 191-193 (2007).
14. Capuzzi DM, Guyton JR, Morgan JM et al.: Effect and safety of an extended release niacin (Niaspan): a long-term study. Am. J. Cardiol. 82, 74-81 (1998).
15. McKenny JM, McCormick LS, Schaefer EJ et al.: Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Amer. J. Cardiol. 88, 270-274 (2001).
16. Guyton JR, Blazing MA, Hagar J et al.: Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoproteins cholesterol. Arch. Int. Med. 160, 1177-1184 (2000).
17. Sakai T, Kamanna VS, Kashyap ML: Niacin, but not gemfibrozil, selectively increases lipoprotein AI, a cardioprotective subfraction of HDL in patients with low HDL cholesterol. Arterioscler. Thromb. Vasc. Biol. 21(11), 1707-1709 (2001).
18. Bays HE, Dujorne CA, McGovern ME et al.: Comparison of once-daily niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin: the ADvicor vs other cholesterol-modulating agents trial evaluation. Am. J. Cardiol. 91. 667-672 (2003).
19. Kashyap ML, McGovern ME, Berra K et al.: Long-term safety and efficacy of once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am. J. Cardiol. 89(6), 672-678 (2002).
20. Vogt A, Kassner U, Hostalek U et al.: Safety and tolerability of extended release nicotinic acid in patients aged >65yrs enrolled in NAUTILUS. Br. J. Cardiol. 13, 278-282 (2006).
21. Oberwittler H, Baccara-Dinet M: Clinical evidence for use of nicotinic acid treatment. Int. J. Clin. Prac. 60, 707-715 (2006).
22. Knopp RH, Alagona P, Davidson M et al.: Equivalent efficacy of a time-release form of niacin (Niaspan®) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 41, 879-881 (1992).
23. Knopp RH: Evaluating niacin in its various forms. Am. J. Cardiol. 86, L51-L56 (2000).
24. Goldberg A, Alagona P, Capuzzi DM et al.: Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am. J. Cardiol. 85, 1100-1105 (2000).
25. Benyo Z, Gille A, Kero J et al.: GPR109A(PUMA-G/HM74A) mediate, nicotinic acid induced flushing. J. Clin. Invest. 115, 3634-3640 (2005).
26. Maciejewiski-Lenoir D, Richman JG, Hakak Y et al.: Langerhans cells release prostaglandin D2 in response to nicotinic acid. J. Invest. Dermatol. 126(12), 2637-2646 (2006)
27. Cheng K, Wu TJ, Wu KK et al.: Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl Acad. Sci. USA 103(17), 6682-6687 (2006).
28. Elam MB, Hunninghake DB, Davis KB et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA 284, 1263-1270 (2000).
29. Grundy SM, Vega GL, McGovern ME et al.: Efficacy, safety and tolerability of on-daily niacin for the treatment of dyslipidemia associated with Type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch. Intern. Med. 162, 1668-1576 (2002).
30. Alsheikh-Ali AA, Karas R: Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, simvastatin alone. Am. J. Cardiol. 99, 379-381 (2007).
31. Sanyal S, Karas RH, Kuvin JT. Present day uses of niacin: effect on lipid and non-lipid parameters. Expert Opin. Pharmacother. 8, 1-7 (2007).
32. Canner PL, Berge KG, Wenger NK et al.: Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J. Am. Con. Cardiol. 8, 1245-1255 (1986).
33. Biankenhorn DH, Nessim SA, Johnson RL et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257(23), 3233-3240 (1987).
34. Cashin-Hemphill L, Mack WJ, Pogoda, JM et al.: Beneficial effects of colestipol-niacin on coronary atherosclerosis. A four-year follow-up. JAMA 264(23), 3013-3017 (1990).
35. Brown G, Albers JJ, Fisher LD et al.: Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323(19). 1289-1298 (1990)
36. Brown BG, Zhao XQ, Chait A et al.: Simvastatin and niacin, antioxidant vitamins or the combination for the prevention of coronary artery disease. N. Engl. J. Med. 345, 1583-1592 (2001).
37. Taylor AJ, Sullenburger LE, Lee HJ et al.: Arterial biopsy for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blinded, placebo controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110, 3512-3517 (2004).
38. Taylor AJ, Lee HJ. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin 22, 2243-2250 (2006).
39. Cefali EA, Simmons PD, Stanek EJ: Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int. J. Clin. Pharmacol. Ther. 44, 633-640 (2006).